Headquartered in Technologielaan 15, Leuven Fiscal year ends December NASDAQ: MTLS materialise.com
Materialise NV provides 3D-printed medical devices, additive manufacturing software, and 3D printing services, drawing on more than three decades of experience. It reports three segments. Materialise Medical, its largest and fastest-growing segment, offers medical software and 3D-printed medical devices. Materialise Software provides open, secure end-to-end additive manufacturing software for industrial manufacturing and mass personalization. Materialise Manufacturing provides 3D printing production services and focuses on markets such as aerospace and defense. Its customers span healthcare, automotive, aerospace, art and design, wearables and consumer goods. The company combines a large group of 3D printing software developers with extensive 3D printing production facilities. In 2026 it divested its RapidFit and Eyewear businesses from the Manufacturing segment, is executing a share buyback program, and is increasing R&D investment in its Medical segment. Shares are listed on Euronext and NASDAQ under MTLS. Updated
Revenue beat expectations while earnings missed, by design: R&D spending rose to chase Medical growth, squeezing that segment's adjusted EBITDA margin to 27.4% from 30.6%. Management reaffirmed full-year revenue and adjusted EBIT guidance even after absorbing the RapidFit and Eyewear divestitures.
Materialise NV provides 3D-printed medical devices, additive manufacturing software, and 3D printing services, drawing on more than three decades of experience. It reports three segments.
The Wall Street consensus 12-month price target for MTLS is $8.73.